We aimed to describe the impact of time to response on the outcomes of 75 patients with accelerated‐phase chronic myeloid leukemia (CML‐AP) at diagnosis. Patients had at least 1 feature of AP: blasts ≥15% (n = 2), basophils ≥20% (n = 19), platelets <100 × 109/L (n = 7), cytogenetic clonal evolution (n = 34), or more than one factor (n = 13). Thirty‐three patients received imatinib; 42 received a second‐generation tyrosine kinase inhibitor (2GTKI) (19 dasatinib and 23 nilotinib). We used chi‐square and Kaplan‐Meier analyses to determine the impact of various degrees of molecular and cytogenetic response at early time points (3 and 6 months) on rates of overall cytogenetic and molecular response, overall survival (OS), event‐free survival (EFS), transformation‐free survival (TFS), and failure‐free survival (FFS). After a median follow‐up of 96 months (range: 18‐224 months), the overall rate of complete cytogenetic response was 79%, of major molecular response, 71%, and of molecular reponse (MR)4.5, 59%. Patients who achieved a major cytogenetic response (MCyR) (n = 49) at 3 months had significantly better 3‐year OS (94% vs 75%; P = .002), TFS (98% vs 73%; P < .001), EFS (93% vs 42%; P < .001), and FFS (83% vs 25%; P < .001) rates than patients who did not have MCyR at 3 months. Most (67%) who eventually achieved sustained MR4.5 had achieved MCyR at 3 months. In de novo CML‐AP, early response at 3 and 6 months is a strong determinant of long‐term outcome.
Background: HSP is typically a disease of children between the ages of 3 and 10 years. Although adult cases have been described, 50% of all cases occur at or before the age of 5 years. Males are affected twice as often as females. In North America, Caucasians have the highest prevalence, and African Americans have the lowest prevalence. Although the cause of HSP is unknown, it commonly follows an upper respiratory tract infection. As a result, the disease is more common in winters.
Objectives:
To determine the prevalence of Henoch-Schonlein purpura (HSP) in children.
To determine the seasonal variation of Henoch-Schonlein purpura (HSP) in children.
Materials and Methods: This was a cross sectional study conducted at Jinnah Postgraduate Medical Center & Karachi Medical & Dental College. Children (<17 yr of age) diagnosed with HSP were included on the basis of non-probability convenient sampling. The diagnosis of HSP was based on the standard defined by the American College of Rheumatology. The sample size calculation was done using the World Health Organization, Geneva software where α=5%, 1-Beta=80, Po=0.15, Pa=0.20, sample size=342. Continuous variables like age and number of patients admitted at various time of year were presented as mean ± standard deviation. Categorical variables, gender and age (<14, >14 years) were presented as proportions.
Results: Mean age of children with HSP was 11 ± 1.5 years. Majority of the children 43.6% were <14 years of age in 2017 and 51.2% in 2018. The annual prevalence of HSP from 2017 till 2018 increased to 9.2%. The frequency of hospitalization also increased, 2017: 40%; 2018: 59%. Males were 71% and females were 28%. Male to female ratio was 2.0. Males >10 years were 29% and females >10 years were 70% (p<0.05) Table1. Number of cases increased from 8-12 years of age and were less frequent in <8 years and >14 years of age. Majority, 20% of cases were of 10 years age. HSP occur all year round with a high prevalence in the winter season. Number of patients increased from 2% in June and July to 58% from November till February.
Conclusion: The overall prevalence of HSP was 19.5 per 1000 affecting children of 9 to 11 years in winters.
Background: Solid tumors with microsatellite instability (MSI), regardless of location, are highly susceptible to immune checkpoint inhibitors. The aim of the study was to investigate clinical and morphological features of tumors with MSI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.